Evidence map›Paper›PMID 37398491›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Tracking SARS-CoV-2 seropositivity in rural communities using blood-fed mosquitoes.

Benjamin J Krajacich, Djibril Samaké, Adama Dao, Moussa Diallo, Zana Lamissa Sanogo, Alpha Seydou Yaro, Amatigué Ziguimé, Josué Poudiougo, Kadiatou Cissé, Mamadou Traoré and 6 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Benjamin J KrajacichLaboratory of Malaria and Vector Research, NIAID, NIH, Rockville, Maryland, USA.
Djibril SamakéMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Adama DaoMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Moussa DialloMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Zana Lamissa SanogoMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Alpha Seydou YaroMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Amatigué ZiguiméMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Josué PoudiougoMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Kadiatou CisséMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Mamadou TraoréMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Alassane Dit AssitounMalaria Research and Training Center (MRTC)/ Faculty of Medicine, Pharmacy and Odontostomatology, University of Sciences, Techniques and Technologies, Bamako, Mali.
Roy FaimanLaboratory of Malaria and Vector Research, NIAID, NIH, Rockville, Maryland, USA.
Irfan ZaidiLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Woodford JohnLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Patrick DuffyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Tovi LehmannLaboratory of Malaria and Vector Research, NIAID, NIH, Rockville, Maryland, USA.
University of Bamako · MLNational Institutes of Health · USVector Oncology (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of SARS-CoV-2 cannot be well monitored and understood in areas without capacity for effective disease surveillance. Countries with a young population will have disproportionately large numbers of asymptomatic or pauci-symptomatic infections, further hindering detection of infection in the population. Sero-surveillance on a country-wide scale by trained medical professionals may be limited in scope in resource limited setting such as Mali. Novel ways of broadly sampling the human population in a non-invasive method would allow for large-scale surveillance at a reduced cost. Here we evaluate the collection of naturally bloodfed mosquitoes to test for human anti-SARS-CoV-2 antibodies in the laboratory and at five field locations in Mali. Immunoglobulin-G antibodies were found to be readily detectable within the mosquito bloodmeals by a bead-based immunoassay at least through 10 hours post-feeding with high sensitivity (0.900 ± 0.059) and specificity (0.924 ± 0.080), respectively, indicating that most blood-fed mosquitoes collected indoors during early morning hours (and thus, have likely fed the previous night) are viable samples for analysis. We find that reactivity to four SARS-CoV-2 antigens rose during the pandemic from pre-pandemic levels. Consistent with other sero-surveillance studies in Mali, crude seropositivity of blood sampled via mosquitoes was 6.3% in October/November 2020 over all sites, and increased to 25.1% overall, with the town closest to Bamako reaching 46.7% in February of 2021. Mosquito bloodmeals a viable target for conventional immunoassays, and therefore country-wide sero-surveillance of human diseases (both vector-borne and non-vector-borne) is attainable in areas where human-biting mosquitoes are common, and is an informative, cost-effective, non-invasive sampling option.

Indexed as

AfricaCOVID-19mosquito blood mealpopulation-based epidemiologysero-surveillance

Identifiers

PMID37398491
PMCPMC10312890
OpenAlexW4380881556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.